CN EN
CN EN

Science & Pipeline

A Robust Drug Discovery Platform Has Been Established
to Develop Novel, Potent and Safe RNAi Therapeutics

Pipeline

Candidate
Indication
Gene Target
Tissue
Proof of Concept
Lead ID
Nonclinical
Phase 1
Phase 2
Phase 3
Ownership
  • SGB-9768
    Autoimmune
    C3
    Liver
    SGB-3908*
    Hypertension
    AGT
    Liver
    Partnered
    SGB-3403
    Hypercholesterolemia
    PCSK9
    Liver
    SGB-3383
    Autoimmune
    CFB
    Liver
    SGB-7342
    Obesity
    INHBE
    Liver
  • Undisclosed
    Obesity
    ACVR1C (ALK7)
    Adipose
    Pending
    Obesity
    Undisclosed
    Muscle
    Pending
    Obesity
    Undisclosed
    Adipose
*SGB-3908: Partnered with Innovent
Hepatic
Extrahepatic
Terms of use | Privacy Policy

Copyright © 2024 Suzhou Sanegene Bio Inc. All rights reserved 

  • Home
  • Phone
  • Top